Paeds Cases · ophthalmology
Explaining why a normal-looking eye needs slit-lamp screening — OSCE
Communication and structured-discussion OSCE on explaining to a parent why a four-year-old child with oligoarticular ANA-positive juvenile idiopathic arthritis needs slit-lamp screening every three months despite a normal-looking eye, covering the silent nature of JIA-associated anterior uveitis, what the slit-lamp looks for (cells and flare), why screening prevents the irreversible complications of band keratopathy cataract glaucoma synechiae and amblyopia, the treatment plan if uveitis is found, and the safety-net features that mean an earlier review.
On this page & tools
Target exams
Candidate instructions (8-minute station)
You are the paediatric registrar in the outpatient clinic. A four-year-old girl has just been diagnosed with oligoarticular ANA-positive juvenile idiopathic arthritis. The paediatric rheumatologist has arranged a baseline slit-lamp examination and explained that she will need eye screening every three months. The mother is anxious — her daughter's eyes look perfectly normal, she has never complained about her vision, and the mother does not understand why she needs to see an eye doctor so often. [7]
-
Explain the silent nature of JIA-associated uveitis — that the inflammation inside the eye produces no redness, pain or visible change in the early stages, so the eye looks normal even when inflammation is present. [7]
-
Explain what the slit-lamp looks for — the ophthalmologist uses a special microscope to look for inflammatory cells and protein haze (flare) inside the anterior chamber, which are invisible to the naked eye but are the signs of active uveitis. [1]
-
Explain why three-monthly screening matters — because untreated uveitis can cause permanent damage to the eye (band keratopathy, cataract, glaucoma, adhesions) and to the developing brain's vision centre (amblyopia), and because catching the inflammation early with treatment prevents this damage entirely. The three-monthly schedule is based on the child's risk profile (ANA positive, oligoarticular JIA, young onset). [7]
-
Outline the treatment plan if uveitis is found — eye drops to reduce the inflammation (prednisolone) and drops to widen the pupil and prevent adhesions (cycloplegic), with specialist medications like methotrexate or a biologic injection if the drops alone are not enough. The treatment is shared between the eye doctor and the rheumatology team. [9]
-
Give a clear safety-net — bring her back sooner if the pupil looks small or irregular, if a white patch appears on the coloured part of the eye, if her vision seems to change, if she squints or holds things close to see, or if the eye becomes red, painful or light-sensitive. [9] [7]
Examiner brief
This station tests the candidate's ability to communicate complex medical information clearly and empathetically to an anxious parent, while demonstrating sound clinical knowledge of JIA-associated uveitis. Look for: a clear explanation of why the eye looks normal (silent disease), what the slit-lamp detects (cells and flare), why frequent screening prevents blindness (early treatment prevents irreversible complications including amblyopia), a calm outline of the treatment plan, and a specific safety-net. The candidate should avoid jargon, acknowledge the mother's anxiety, and check understanding throughout. [7] [1]
References
- [1]Jabs DA; Nussenblatt RB; Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol, 2005.PMID 16196117
- [7]Angeles-Han ST; Yeh S; Vogel LB; et al 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care Res (Hoboken), 2019.PMID 31021540
- [9]Modrzejewska M; Grzybowski A; Misiuk-Hojlo M; et al Diagnosis and Treatment of Uveitis in Children: A Summary of the Latest Data from a 5-Year Literature Review. J Clin Med, 2024.PMID 38892808